Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17010319 | 1.00 | POLB (0.52) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL30285813 | 0.85 | CYP1A2 (0.60) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL545821 | 0.85 | CYP1A2 (0.60) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL345499 | 0.81 | BRAF (0.61) | BRAF | |
| SCHEMBL25131740 | 0.81 | EGFR (0.56) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL29007791 | 0.78 | MAPT (0.47) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL28054973 | 0.78 | POLB (0.46) | POLBKMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL6508127 | 0.78 | CGAS (0.44) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL6508122 | 0.78 | CGAS (0.44) | POLBKMT2AMAPTMEN1SMN1; SMN2 | |
| SCHEMBL2466036 | 0.77 | MAPT (0.46) | POLBKMT2AMAPTMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | ACQUIST LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | ACQUIST LLC | 2017-07-13 | — | — | US | disclosed |
| EP-3104861-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | Warrell, Raymond P., Jr. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123003-A1 | BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS | WARRELL RAYMOND P (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197923-A1 | Bifunctional Compounds and Use for Reducing Uric Acid Levels | XDH, OAT, ATIC | POLB 1443/4885KMT2A 3511/4885MAPT 3426/4885 |
| US-10093631-B2 | Bifunctional compounds and use for reducing uric acid levels | XDH, OAT, ATIC | POLB 1443/4885KMT2A 3511/4885MAPT 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.